Today announced that its board of directors has named Selene Flores as its new president and chief executive officer

Houston, Jan. 23, 2011 /PRNewswire/ -- GenNxeix, Inc. Today announced that its board of directors has named Selene Flores as its new president and chief executive officer. Selene, who will also become a member of its Board of Directors, starts at GenNxeix on January 24th.

"After an extensive and thorough search, we're delighted to have selected Flores as our new CEO," said GenNxeix company founder and board chairman Robert Graham Ph.D. "Flores is a terrific product executive who has also demonstrated exceptional business and leadership skills. She's a perfect fit to take GenNxeix into the future. We will leverage Flores' extensive background in customer-driven product strategy and delivery to ensure GenNxeix' strategic plan is focused and optimized for growth."

"Honored to be joining GenNxeix, an industry pioneer in Genomic science applications and services," Flores said. "While there's a lot of work to do, GenNxeix has incredible and unique assets upon which to build, including a very talented team. I'm excited about the opportunity to help lead GenNxeix on to the next great chapter in its success. "


Flores will be taking over from Rose Conrad, who has served as CEO since March 1999. Conrad, who has been an executive at GenNxeix since 1998,

GenNxeix creates innovative Genomic Biotech applications and services that make it easy for Cancer Patients to make intelligent decesions about chemotherapy. GenNxeix invented the GenNxeix Breast Cancer Toolkit aiming to support every Breast Cancer Patient, Clinical Trial, and Doctors Office Find corporate information at www.GenNxeix.com/


GenNxeix is a registered trademark of GenNxeix, Inc. All other trademarks, names of actual companies and products mentioned herein are the property of their respective owners.

Forward Looking Statements: This press release contains forward-looking statements that involve risks and uncertainties, including statements relating to the future success of GenNxeix. More information about potential risk factors that could affect business and financial results is included in the GenNxeix annual report on Form 10-K for the most recent year ended December 31, and its quarterly reports on Form 10-Q and, from time to time, in other reports filed by GenNxeix. Actual results may differ materially from estimates under different assumptions or conditions. GenNxeix assumes no obligation to update any forward-looking statements or information, which are in effect as of their respective dates.

SOURCE GenNxeix, Inc.

New Break in the Fight Against Breast Cancer

Hybrid Pharmaceutical GenNxeix , the Genomics Biotech Engineering company, CEO Selene Flores gives us
New break in the fight against breast cancer is a science. From MD Anderson Houston TX,

New break in the fight against breast cancer, is a science term called autophagy. Autophagy is a biological process involving self-digestion of breast cellular material when breast cells are
deprived of nutrients or in stress. In most cases, Autophagy acts as a breast cell survival mechanism protecting breast cells from different types of stress. Autophagy has been shown to play roles in normal physiological processes including energy metabolism, organelle turnover, growth regulation, and aging. Impaired breast autophagy leads to cancer. Autophagy has also been implicated in the cellular response to anti-breast cancer therapies.

Identification and characterization of regulators of autophagy in patient samples, breast cancer cell line and mouse models is a area of research that GenNxHybrid GenNxeix scientist in Galveston Texas focus on.

GenNxeix functional genomics, and proteomics approaches to identify and characterize factors required for breast cell death and autophagy in the clinical breast cancer samples. GenNxeix pharmacodynamics and pharmacokinetic effect on autophagy in anti-cancer therapy. Alteration of autophagy in endocrine therapy, chemotherapy and/or irradiation therapy is the nature tested. Evidence suggests that autophagy acts as a tumour suppressor and should be stimulated to decrease the incidence of cancer in breast cells. Analysing the reletionship between tumour suppression and autophagy genes in breast cancer.

Autophagy is an evolutionarily conserved mechanism of cellular self-digestion in which proteins and organelles are degraded through delivery to lysosomes. GenNxeix notice defects in this process is implicated in breast cancer. To understand autophagy, we performed a functional screen in search of microRNAs (miRNAs), which regulate the autophagic flux in breast cancer cells. As a result GenNxeix Scientist identified the tumour suppressive miRNA, miR-101, as a potent inhibitor of basal, etoposide- and rapamycin-induced autophagy. GenNxeix Scienyidt uses transcriptome to identified three novel miR-101 targets, ”STMN1″, ”RAB5A” and ”ATG4D”. where siRNA-depletion of these genes phenocopied the effect of miR-101overexpression, to demonstrating the genes importance in autophagy regulation. Importantly, overexpression of ”STMN1″could partially rescue cells from miR-101-mediated inhibition of autophagy. As a Result miR-101-mediated inhibition of autophagy will sensitize breast cancer cells to 4-hydroxytamoxifen mediated cell death. This is a classic case where genomics is here to stay.